India's Agni long-range missiles broke UN limits, says China

January 5, 2017

Beijing, Jan 5,: India has "broken" UN limits on nuclear arms and long-range missiles and Pakistan should also be accorded the same "privilege", state-run Chinese media said today as it criticised New Delhi for carrying out Agni-4 and 5 missile tests whose range covers the Chinese mainland.

agni

"India has broken the UN's limits on its development of nuclear weapons and long-range ballistic missile," the ruling Communist Party-run tabloid Global Times said in its editorial.

"The US and some Western countries have also bent the rules on its nuclear plans. New Delhi is no longer satisfied with its nuclear capability and is seeking intercontinental ballistic missiles that can target anywhere in the world and then it can land on an equal footing with the UN Security Council's five permanent members," it said.

"India is 'promising' in vying for permanent membership on the UN Security Council as it is the sole candidate who has both nuclear capability and economic potential," it said.

"China should realise that Beijing wouldn't hold back India's development of long-range ballistic missiles," it said apparently highlighting China's limitations in restricting India developing a nuclear and missile deterrence against Chinese military power.

Agni-5, a 5,000-km range intercontinental ballistic missile (ICBM), is widely regarded as a strategic missile targeted at China as it can reach almost all parts of the Chinese mainland.

The editorial said that "Chinese don't feel India's development has posed any big threat to it".

The daily known for its sabre-rattling rhetoric said "India wouldn't be considered as China's main rival in the long run" due to vast disparity of in power between the two countries.

But at the same time it suggested that the "best choice for Beijing and New Delhi is to build rapport".

However, while accusing India of violating limits imposed by UN on nuclear and long range missile development, "if the Western countries accept India as a nuclear country and are indifferent to the nuclear race between India and Pakistan, China will not stand out and stick rigidly to those nuclear rules as necessary", it said.

"At this time, Pakistan should have those privileges in nuclear development that India has," it said, indicating that China which shared an all-weather ties with Islamabad will back it if it develops long-range missiles.

"In general, it is not difficult for India to produce intercontinental ballistic missiles which can cover the whole world. If the UN Security Council has no objection over this, let it be. The range of Pakistan's nuclear missiles will also see an increase. If the world can adapt to these, China should too," it said.

The references to violation of UN rules by the daily were significant as the Chinese Foreign Ministry spokesperson Hua Chunying while reacting to India's Agni-5 missile test said on December 27 that"on whether India can develop this ballistic missile that can carry nuclear weapons, I think relevant resolutions of the UNSC have clear rules".

Comments

Rikaz
 - 
Thursday, 5 Jan 2017

Good, China is scared of us.....

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
January 5,2020

New Delhi, Jan 5: A masked mob on Sunday entered the Sabarmati Hostel on the Jawaharlal Nehru University (JNU) campus and assaulted several students and professors with sticks and rods.

"I have been brutally attacked by goons wearing masks. I am bleeding. I was brutally beaten up," JNU Students' Union (JNUSU) president Aishe Ghosh told reporters.

She has been admitted to the AIIMS here for treatment.

Several other students were also injured in the incident.

In a video of the incident, a group of goons with their faces covered can be seen assaulting students with wooden sticks and rods.

A tweet from the official handle of the JNUSU said, "Sabarmati Hostel: right now. They are beating the students who are inside. Knocking on doors with rods. People are jumping from balconies. #SOSJNU #EmergencyinJNU."

"Professors who were trying to protect us have been beaten up. These are unknown ABVP goons, not all are students, they have covered their faces, and they are moving towards the hotels near the West Gate. Stay alert. Make human chains. Protect each other. #SOSJNU #EmergencyinJNU," another tweet added.

Meanwhile, the ABVP's JNU unit claimed in a tweet: "Emergency in JNU. Leftist goons of JNU accompained with their cadre from other universities have crossed every limit. They have proceeded with unimaginable violence on ABVP activists of JNU."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 30,2020

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 8,2020

New Delhi, Jul 8: India has reported a spike of 22,752 COVID-19 cases in the last 24 hours, taking the country's coronavirus tally to 7,42,417 on Wednesday, informed the Union Ministry of Health and Family Welfare.

Out of the total cases reported, 4,56,830 patients have been cured/discharged from the disease while one patient has been migrated, the Health Ministry informed.

It added that there are 2,64,944 active cases in the country.

482 deaths reported in the last 24 hours due to COVID-19 in the country, taking India's death toll to 20,642.

According to the Union Health Ministry, Maharashtra continues to be the worst affected state reporting 2,17,121 coronavirus cases and 9,250 fatalities.

Tamil Nadu -- the second worst-affected state from COVID-19 -- has a total of 1,18,594 cases and 1,636 deaths due to coronavirus.

While Delhi has a total of 1,02,831 COVID-19 cases including 3,165 deaths.

The Indian Council of Medical Research on Wednesday informed that a total of 1,04,73,771 samples tested for COVID-19 up to July 7. Of these, 2,62,679 samples were tested on Tuesday.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.